# A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

> **NCT02996838** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQ-B3234

## Key facts

- **NCT ID:** NCT02996838
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-11
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996838, "A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02996838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*